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ABSTRACT 
Purpose: To measure the charge to mass (Q/M) ratios of the impactor stage masses (ISM) from 
commercial Flixotide™ 250 µg Evohaler, containing fluticasone propionate (FP), Serevent™ 25 µg 
Evohaler, containing salmeterol xinafoate (SX), and a combination Seretide™ 250/25 µg (FP/SX) 
Evohaler metered dose inhalers (MDIs). Measurements were performed with a purpose built bipolar 
charge measurement apparatus (bp-NGI) based on an electrostatic precipitator, which was directly 
connected below Stage 2 of a next generation impactor. 
Methods: Five successive shots of the respective MDIs were actuated through the bp-NGI. The whole 
ISM doses were electrostatically precipitated to determine their negative, positive and net Q/m ratios.   
Results: The ISM doses collected in the bp-NGI were shown to be equivalent to those collected in a 
standard NGI. FP particles, actuated from Flixotide™ and Seretide™ MDIs, exhibited greater quantities 
of negatively charged particles than positive. However, the Q/m ratios of the positively charged particles 
were greater in magnitude. SX particles from Serevent™ exhibited a greater quantity of positively 
charged particles whereas SX aerosol particles from Seretide™ exhibited a greater quantity of 
negatively charged particles. The Q/m ratio of the negatively charged SX particles in Serevent™ was 
greater in magnitude than the positively charged particles.  
Conclusions: The bp-NGI was used to quantify the bipolar Q/m ratios of aerosol particles collected 
from the ISMs of commercial MDI products. The positive charge recorded for each of the three MDIs 
may have been enhanced by the presence of charged ice crystals formed from the propellant during the 
aerosolisation process.   
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INTRODUCTION  
A metered dose inhaler (MDI) typically consists of a coated or uncoated aluminium can, a crimped 
metering valve containing a solution or suspension based formulation of an active pharmaceutical 
ingredient (API), held under pressure within a liquefied propellant such as HFA 134a or HFA 227. 
Formulations may also require the addition of a surfactant(s), to stabilise the dispersion of the API within 
the formulation (1). While in suspension, API particles come into contact with the inner walls of the 
canister, metering chamber and the components of the metering valve (elastomers, spring and stem) 
(2). For both HFA 134a and 227, the increased polarity compared to the original CFC propellants 
significantly increases the availability for the uptake of water. Thus, when formulating a suspension MDI 
the physical stability may be influenced by the amount of water in a formulation and the ingress rates of 
moisture via the metering valve. 
 
The major factor that links the properties of the formulation to the respirable dose is the atomisation 
process. The actuation of an MDI, initiated by the depression of the valve stem, leads to the discharge 
of a metered volume via an expansion chamber. This process leads to high shear flow and flash 
evaporation of the liquefied propellant, created by the sudden decrease in pressure. The resultant 
droplets enter a highly kinetically energetic state, undergoing numerous collisions with each other and 
with the inner surfaces of the valve stem and the actuator orifice before being emitted from the actuator 
as a jet spray. During these collisions electron transfer may occur to or from the API particles via the 
mechanism of triboelectrification, causing the creation of highly charged species (3). Due to the multi-
component nature of the system, the precise mechanisms remain relatively poorly understood; although 
it has been hypothesised that charge transfer may occur as a result of differences in the electrical 
properties of the materials involved. The canister and spring are generally constructed of conductive 
metals, although the inner surfaces of the aluminium cans can be coated with a low surface free energy 
polymer, whereas the valve, valve seals, stem are generally made from insulating plastics. The API 
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particles, which are electrically resistive, may also come into contact with the inner surfaces during which 
time charge transfer may occur. The amount of charge transferred will depend on the difference between 
the effective work functions of the two materials coming into contact, which is a measure of how much 
energy is required to remove an electron from the Fermi level of the material to the vacuum energy level 
(4). Charge transfer ceases when the Fermi levels of the two materials become equal, minimising the 
energy difference (5). In addition, as the HFA transitions into the vapour phase, rapid evaporative cooling 
will occur which may result in any soluble water present forming solid ice crystals which may also carry 
a charge (6). 
 
As a result of these complex surface interactions experienced between the pMDI formulation and device 
components, aerosolised drug particles emitted may become both negatively and positively charged, 
resulting in a bipolar charge distribution, which may be difficult to accurately measure using conventional 
net charge measurement methods.  
 
Various attempts have been made to accurately quantify the charge build up on aerosol particles in 
proportion to their mass. Ali et al. utilised an electrical single particle aerodynamic relaxation time 
(ESPART) analyser to determine electrodynamic effects of some sample DPI and pMDI formulations 
(7). Although the system provides measurements of bipolar charge-to-mass ratio, only single particle 
measurements may be recorded and not the entire deposited aerosol dose per shot. In addition, the 
ESPART measures charge and particle size by the particle number and not by mass or volume. 
Conversion of the distributions from a number based system may introduce error and so the data from 
the ESPART may be of limited relevance for pharmaceutical aerosols. The first widely available 
commercial method developed was the ELPI (electrical low pressure impactor) in which a Berner-type 
multi-jet low pressure impactor was modified such that the impaction plates are electrically isolated and 
connected to electrometers allowing for simultaneous net charge measurements and mass 
quantifications to be performed (8). Glover and Chan used the ELPI to measure the net charge of both 
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Flixotide™ and Ventolin™ pMDIs (9). For Flixotide™, they found that at higher particle cut off diameter, 
an overall net negative charge was recorded. At lower particle cut off diameter, an overall net positive 
charge was recorded. When plotted against the mass of deposited fluticasone propionate (FP) particles, 
at the lower cut off diameters, almost no FP was deposited, but a large net positive charge was recorded. 
This may be due to the presence of water which forms ice crystals during the actuation of the pMDI, the 
mass of which cannot be determined by conventional chromatographic methods (6). The study was 
further expanded to include Intal™, Tilade™ and QVAR™ pMDIs together with Flixotide™ and 
Ventolin™ (10). 
 
The principles governing the mode of operation of the ELPI were used in the development of the 
Electrical Next Generation Impactor (eNGI), in which insulated NGI impaction cups are connected to an 
electrometer and the net charge-to-mass ratios of aerosol particles determined (11). The eNGI was 
successfully used to determine the effect of flow rate on the net charge-to-mass ratios of the Fine 
Particle Fraction (FPF) of Flixotide and Seretide pMDIs (12). Both the ELPI and eNGI allow the mass of 
the aerosol particles to be quantified but do not take into account the bipolar nature of the aerosol 
particles, providing only a measurement of the net electrostatic charge. 
 
By utilising electrostatic precipitation, positively and negatively charged aerosol particles may be 
separated by means of an electric field generated by a high voltage source (13). Early systems such as 
those developed by O’Leary et al. and Kulon et al. allowed for the bipolar charge-to-mass ratios of 
aerosol particles to be measured (14, 15). However, these systems were not ideally suitable for 
performing accurate quantification of the amount of aerosol particles deposited and as such did not 
allow accurate measurement of bipolar charge-to-mass ratios to be performed.  
 
More recently Dekati Ltd. have developed a novel instrument for measuring the electrostatic charge of 
aerosol particles called the BOLAR™. The instrument is designed such that the principal of electrostatic 
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precipitation is combined with an aerodynamic particle size classification system which allows for the 
bipolar charge-to-mass ratios of five different size fractions to be determined (16). Wong et al. used the 
system to measure the bipolar charge-to-mass ratios of spray dried mannitol particles from an 
Osmohaler® at flow rates of 30 and 60 L/min (17). The same authors then used modified Aerolizer™ 
devices to investigate the effect of inhaler design and inhaler material on the bipolar charge-to-mass 
ratios of spray dried mannitol particles (18). The BOLAR™ system was further used by Leung et al. to 
determine the bipolar charge-to-mass ratios of five particle size ranges for Intal Forte®, Tilade®, 
Ventolin® and QVAR® pMDIs at a flow rate of 60 L/min. The data showed QVAR® pMDI, which is a 
solution formulation, produced aerosol particles with a significantly different bipolar charge to mass 
distribution than the three other suspension type pMDIs (19). The authors further utilised the BOLAR™ 
to assess the use of a spacer on the bipolar charge-to-mass ratios of Tilade® pMDI. Interestingly, while 
the magnitude of the charge present on the positively charged respirable particles remained similar, the 
magnitude of the charge of the negatively charged particles was shown to decrease, along with the fine 
particle dose (20). 
 
The present study introduces an additional tool to classify the bipolar charge-to-mass ratios of respirable 
aerosol particles. The set up consists of a modified Next Generation Impactor (NGI) which is an industry 
standard aerosol particle size classifier used to determine the in vitro performance of inhalable drug 
products (21). An electrostatic precipitation system is connected to a stage 2 of the NGI to allow 
measurement of the charge-to-mass ratio of the impactor stage mass (ISM). In addition, the complete 
emitted dose (ED) was recovered from the system in order to maintain accurate determination of the 
inhaler performance as would be determined by a normal NGI which has not been possible with other 
bipolar charge measurement systems previously developed. This bipolar Next Generation Impactor (bp-
NGI) has been successfully used to characterise the bipolar charge to mass distributions of Flixotide™ 
250, Serevent™ 25 and Seretide™ 250 pMDIs. 
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MATERIALS AND METHODS 
Materials 
Flixotide™ 250, Serevent™ 25, Seretide™ 250/25 Evohalers are suspension based pressurised 
metered dose inhaler (pMDI) formulations delivering 250µg of fluticasone propionate (FP), 25 µg 
salmeterol xinafaote (SX) and a combination of 250µg FP and 25 µg SX per actuation, respectively. 
These formulations contain the APIs suspended in HFA 134a propellant and were manufactured by 
GlaxoSmithKline (Ware, UK). Commercial samples of the pMDIs were supplied by AAH 
Pharmaceuticals Ltd. (Coventry, UK). Fluticasone propionate was supplied by Chemagis Ltd (Bnei Brak, 
Israel) and salmeterol xinafoate supplied by Neutech Laboratories (Hyderabad, India). All solvents used 
were of HPLC grade (Sigma-Aldrich, St. Louis, MO, USA). Ultra pure water was produced by reverse 
osmosis (MilliQ, Millipore, Molsheim, France). Ammonium acetate was purchased from Sigma Life 
Sciences (St. Louis, MO, USA). 
 
Methods 
Quantification of pMDI performance using the Next Generation Impactor (NGI) 
 
The performance of the pMDIs was determined using a conventional NGI at 30 L/min (21). Five shots 
were actuated through the system. The APIs were recovered from the MDI actuator, mouthpiece and 
throat and collection cups. For stages 1-5 of the NGI the collection cups were washed with 20 mL of 
mobile phase, cups for stages 6-7 were filled with 5 mL of mobile phase and the cup for the MOC was 
filled with 10 mL of mobile phase to recover the API. Chemical analysis of the concentrations of the APIs 
was analysed using HPLC. 
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Design of the bipolar Next Generation Impactor (bp-NGI) 
A schematic representation of a modified next generation impactor (NGI), incorporating two electrostatic 
precipitators for the collection of charged aerosols from any number of stages of an NGI (stage 2 through 
to stage 7) is shown in Figure 1. The modified system is known as the bipolar next generation impactor 
(bp-NGI). The bp-NGI was designed to collect and measure the charge-to-mass ratios of negatively and 
positively charged aerosol particles below a well-defined cut-off aerodynamic diameter.  
In this study, the electrostatic precipitators were attached to stage 2 of the NGI, with a cut-off diameter 
of 6.40 µm at a flow rate of 30 L/min. The flow rate was controlled by a flow controller (TPK, Copley 
Instruments, Nottingham, UK) attached to a vacuum pump which was connected to the base of the 
electrostatic precipitators. Below the collection cup of stage 2, the aerosol dose is bifurcated into the 
two precipitators with an airflow rate of 15 L/min being pulled through each section. Each precipitator 
contained an earthed outer tube, to create a Faraday shield, a precipitation tube, a filter holder and a 
high voltage electrode, which was centrally positioned within the precipitation tube. 
The bp-NGI was also designed to maintain laminar flow through the precipitators. The critical dimensions 
of the two electrostatic precipitators were designed to maximise the collection efficiency (Kprecip) of the 
electrically mobile aerosol particles by adapting methodology used by Kulon et al. (22). The collection 
efficiency was determined using Equation 1. 
𝐾𝑝𝑟𝑒𝑐𝑖𝑝 (%) =  
2
𝑟2
√
𝑍𝑝𝑉𝐿
𝑣𝑜 ln(𝑟2 𝑟1⁄ )
 × 100  Equation 1 
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Where 𝑍𝑝 is the electrical mobility of the charged aerosol particle, V is the voltage on the central 
electrode, L is the length of the electrode, 𝑣𝑜 is the airflow rate, 𝑟1 is the radius of the electrode and 𝑟2 is 
the radius of the precipitation tube. 
The calculated collection efficiencies of the bp-NGI at ±3.0 kV are shown in Figure 2 for aerosol particles 
exhibiting different amount of electrical charge at the cut-off diameters of the NGI stages at 30 L/min. 
Electrical mobilities of the particles were calculated according to Equation 2. 
𝑍𝑝 =
𝑛𝑒
6𝜋𝜂𝑎𝑖𝑟𝑟𝑝
 Equation 2 
Where n is the number of elementary charges on the particle, e is the elementary charge, 1.602 x 10-19 
C, ηair is the viscosity of air at 25 °C, and rp is the radius of the particle. The density of the particles was 
assumed to be 1 g/cm3. The theoretical calculations suggested that particles below 6.40μm in diameter 
will be reasonably efficiently collected at ±3.0 kV, with a near maximum collection efficiency occurring 
when a particle gains a negative or positive charge equivalent to 200 electron charges per particle. 
 
Methodology for Performing Bipolar Charge to Mass Measurements of Respirable Drug Particles 
Using the bp-NGI 
Opposite polarity high DC voltage sources (Spellman, CZE1000R, West Sussex, UK) were connected 
to the electrically insulated copper electrodes, centrally located in the respective precipitators. A -3 kV  
voltage was applied to the negative electrode and a +3 kV to the positive electrode throughout this study. 
Aerosol particles with low electrical mobility, which cannot be precipitated onto either the electrodes or 
the precipitation tubes, were collected onto 0.45 μm pore size glass fibre filters (Whatman, Fisher 
Scientific, UK), housed at the base of each precipitation tube. The system is modular, such that each 
section of the apparatus can be isolated and separately washed down for drug quantification via HPLC.  
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During operation, the precipitation tubes were connected to a Keithley Instruments 6521 multi-input 
scanner card (Keithley Instruments, Reading, UK) connected to a Keithley 6517B electrometer for 
charge measurements. For each actuation of the inhaler device into the bp-NGI, the current versus time 
(I vs t profiles) profiles during aerosol deposition onto the two precipitation tubes were recorded and 
subsequently integrated to measure the positive and negative charge collected per shot. The cumulative 
amount of positive and negative charge for a well-defined number of shots was also measured. These 
values were divided by the total mass of drug collected within the positive and negative precipitation 
tubes to determine the net charge-to-mass ratio of the negatively and positively charged aerosols.  
During all experiments, the operator was connected to earth via a wrist band and the outer tubes 
surrounding the electrostatic precipitators were earthed to shield the precipitation tubes from stray 
external fields. During each experiment, a total of five shots of Flixotide™ 250, Seretide™ 250 and 
Serevent™ 25 were fired through the bp-NGI. The mass of the negatively, positively and neutrally 
charged particles was quantified via HPLC to calculate the bipolar charge to mass distribution within the 
bp-NGI. The experiments were performed in triplicate for statistical robustness. The temperature range 
for all experiments was 20°C ± 1 and the humidity range was 40% ± 2. 
During operation, the electric field created by the negative electrode repels the negatively charged 
aerosol particles onto the negative precipitation tube, while the positively charged aerosol particles are 
attracted onto the electrode. Conversely, negatively charged aerosol particles in the oppositely charged 
precipitator are deposited onto the positive electrode while the positively charge aerosols are repelled 
onto the positive precipitation tube. The amount of drug collected on the negative precipitation tube and 
positive electrode indicated the quantity of drug particles that have sufficient negative electrical mobility 
to be precipitated within the two precipitators. The quantity of drug collected on the positive precipitation 
tube and negative electrode indicated the quantity of drug particles that are positively charged. The 
mass of drug collected from the respective filters represent the amount of aerosol dose which has 
insufficient positive or negative electrical mobility to be precipitated. 
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HPLC Analysis of Fluticasone Propionate and Salmeterol Xinafoate 
Determination of the mass distribution of fluticasone propionate (FP) and salmeterol xinafoate (SX) was 
adapted from a previously published HPLC method (23). The HPLC system consisted of a pump (Jasco 
PU-980, Jasco Corp., Japan) coupled to an autosampler (Jasco AS-950) and UV detector (Jasco UV-
975) set at 228 nm for simultaneous determination of both APIs. Separation was performed using a BDS 
Hypersil Column, 250x4 mm (Thermo Scientific, Waltham, MA, USA) maintained at 40⁰C using a column 
oven (Jasco CO-965). The mobile phase was a mixture of methanol–0.6% (w/v) aqueous ammonium 
acetate solution (75:25%, v/v), filtered through a 0.45 μm nylon membrane (Whatman International Ltd., 
Maidstone, UK) and degassed. The retention time for salmeterol was 4.4 minutes and for fluticasone 
propionate was 5.4 minutes. Quantification was carried out by an external standard method and linearity 
was checked between 0.5 and 50 μg/mL for each individual API.  
 
Statistical analysis 
Linear regression analysis was used for the assessment of HPLC calibration. Statistical analysis 
between different populations was carried out using one-way analysis of variance. Comparison of the 
mean values was performed by Tukey’s pair-wise comparison. All statistical analyses were performed 
using GraphPad Prism software (GraphPad Software Inc, California, USA). Error bars in graphical 
representations of data show ± standard deviation (S.D.) in all cases. 
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RESULTS AND DISCUSSION 
Flixotide™ 250 and Serevent™ 25 pMDI were first tested with a conventional NGI in order to determine 
their conventional in vitro performance and to provide a comparison with the performance of the bp-
NGI. The bp-NGI apparatus was connected to Stage 2 of the NGI and for each of the pMDIs, the mass 
deposition profiles within the electrostatic precipitators and bipolar charge measurements of the APIs 
were measured at both 0 V and ±3 kV. These measurements were then used to calculate the charge-
to-mass ratios of both the negatively and positively charge aerosols generated by each pMDI.  
 
Comparison of Conventional NGI and bp-NGI performance 
A summary of the emitted doses and impactor stages masses for each API (as a percentage of the 
recovered dose) from Flixotide™ and Serevent™ pMDIs, as determined with a conventional NGI and 
with the bp-NGI (with electrostatic precipitators set to 0 Volts) are summarised in Table i. For each pMDI 
the results from each performance indicator were comparable, indicating that the addition of the 
electrostatic precipitation system to the bp-NGI had not adversely affected its ability to classify pMDI in 
vitro performance.  
 
Bipolar charge-to-mass ratio determination of Flixotide™ 250 
The mass deposition profile of FP from a commercial Flixotide™ 250 pMDI on the various sections of a 
bp-NGI at 0 V and ±3 kV are shown in Figures 3A and 3B, respectively, and summarised in Table ii. 
These data are expressed in terms of the mean quantity of drug deposited on each of the precipitation 
tubes, electrodes and filters and the relative percentage of the total amount of drug entering each 
precipitation section. When no voltage was applied to the central electrodes of the bp-NGI, over 95% of 
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the dose was recovered on the filters. The minimal deposition of FP on the electrodes and precipitation 
tubes at 0 V suggested laminar flow was maintained within each section. At 0 V, there was no significant 
difference (p > 0.05) in the quantities of FP entering each precipitation section of the bp-NGI (150.0 ± 
10.7 μg and 149.4 ± 6.8 μg), indicating efficient bifurcation of the aerosol dose. 
Upon applying -3 kV and +3 kV to the central electrodes of the two precipitators, similar quantities of FP 
were recovered, with only a relatively small percentage of the dose being collected on the filter. The 
percentage of aerosol particles collected on the negative and positive filters at ± 3.0 kV was 13.0 ± 1.2% 
and 11.6 ± 1.6%, respectively.  For the positive precipitator section (+3.0 kV), 64.7 ± 1.4% of the mass 
collected was recovered on the central electrode, with 23.8 ± 1.7% of the aerosol particles precipitating 
on the positive precipitation tube. For the negative precipitator section (-3.0 kV), 25.0 ± 3.2% of the mass 
was collected on the central electrode, with 62.0 ± 2.3% on the negative precipitation tube.  The mass 
ratios of the negatively to positively charged particles on the positive and negative sections of the bp-
NGI were an average of 2.6:1. These data suggest that FP particles undergo sufficient triboelectrification 
upon aerosolisation to be electrostatically precipitated. These data also suggest that the FP particles 
are bi-polar in nature with the greater amount of particles less than 6.40 μm being negatively charged.   
Individual shot-by-shot charge measurements on the precipitation tubes (labelled negative and positive) 
and their net charge values at 0 V and ±3.0 kV are shown in Figure 4A and 4B, respectively. Measuring 
in current versus time mode at 0 V, each precipitation section acts as a flow through Faraday pail, 
operating in a similar fashion to a system utilised by Chow et al. (24). At 0 V, both sections exhibited a 
net positive charge (average +0.04 ± 0.00 nC), which is in agreement with the research findings of Peart 
et al., that showed unlike the majority of marketed pMDI products, GSK’s US FP pMDI product 
(Flovent®) consistently produced a net positively charged aerosol cloud (25). Conversely, Hoe et al., 
who used an electrical Next Generation Impactor (eNGI) to measure the net charge of Flixotide™ and 
Seretide™ on individual stages at three different flow rates, found that the net charge-to-mass ratios for 
particles of FP and SX were slightly negative and close to zero on a pC/μg level (12). Kwok et al. used 
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a Faraday well and an ELPI to measure the net charge-to-mass ratios of a range of pMDIs, including 
Flixotide™ (10). The overall net charge of the entire dose of a Flixotide™ pMDI as measured with a 
Faraday well was also found to be net positive, whereas on the individual stages of the ELPI the net 
charge on the stages which retained significant amounts of FP were net negative. However, on the lower 
stages of the ELPI (approximately <0.6 µm), where there was minimal drug recovery or the recovery 
was below the limit of detection, there was a polarity change and a significant amount of net positive 
charge was recorded. Since the number of elementary charges per droplet is well below the Raleigh 
limit, the possible source of this charge was purported by Kwok et al. to be possibly due to the presence 
of non-volatile water in the MDI, which may precipitate as small ice crystals from an evaporating HFA 
droplet (26). The ingress of water has also been shown to affect charging of the fine particle dose in a 
HFA-134a pMDI by Kulphaisal et al., who showed that when the water content increased above 300ppm 
the net charge inverted from negative to positive (6).    
Upon applying -3 kV and +3 kV DC voltage to the respective negative and positive electrodes, the mean 
charge of the negatively charged FP particles per shot was recorded as -0.36 ± 0.01 nC, and the mean 
charge of the positively charged FP particles per shot was +0.43 ± 0.01 nC. The polarity of the net 
charge of the fine particle cloud per shot was electropositive and calculated to be +0.07 ± 0.01 nC. The 
net charge measurements for the aerosol dose below ≤ 6.4 μm at both 0 V and ± 3 kV are in good 
agreement with the previous findings (10). 
The bipolar charge to mass (Q/m) ratio of the negative and positive charges from a Flixotide™ 250 pMDI 
are shown in Figure 5. The Q/m ratios of the negatively and positively charged particles were -18.0 ± 
2.8 pC/μg and +68.8 ± 5.6 pC/μg, respectively. Whilst these data suggest that the charge per unit mass 
of the positively charged FP particles were significantly larger in magnitude than the negatively charged 
particles, the bp-NGI measurements do not account for the possible charging effects of the excipients 
and from the precipitation of ice crystals.  
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Bipolar charge-to-mass ratio determination of Serevent™ 25 
The mass deposition profile of SX from a commercial Serevent™ 25 pMDI on the various section of the 
bp-NGI at 0 V and ±3 kV are shown in Figures 6A and 6B, respectively, and are summarised in Table 
iii.  At 0 V, over 88% of the particles were collected on the filters, with no significant differences in the 
quantities entering each precipitator and the drug collected on the glass filters (p > 0.05).   
Applying ±3 kV potential to the central electrodes significantly reduced the deposition of SX on the filters 
(p < 0.05). The percentage of low electrical mobility particles recovered from the filters dropped to below 
14%. For both precipitators, there was a significantly greater recovery of positively charged SX particles 
than negatively charged SX particles. The mass ratio of positively charged to negatively charged 
particles in both precipitators was approximately 3:1.  
Shot-by-shot charge measurements from the outer precipitation tubes for five consecutive shots at 0 V 
and ±3 kV are shown in Figures 7A and 7B, respectively. With no voltage being applied, the net charge 
of the SX particles was low and slightly electropositive for both precipitators. These data are not in 
agreement with net fine particle dose charge measurements of Peart et al., who found, with the use of 
an aerosol sampling apparatus, the net charge of SX was electronegative (-80 pC) (25).    Applying -3 
kV and +3 kV DC voltage to the respective negative and positive electrodes, there was no significant 
differences in the mean charge per shot of the negatively and positively charged SX particles (Table iv) 
The charge to mass (Q/m) ratios of the negatively and positively charged particles were -106.2 ± 23.4 
pC/μg and +43.7 ± 3.3 pC/μg, respectively, and the overall net charge-to-mass ratio was +3.7 ± 4.5 
pC/μg as shown in Figure 8. 
In a similar trend to the Flixotide study, the low precipitated mass of SX particles (negatively charged 
SX) exhibited a significantly higher Q/m ratio than the higher precipitated mass. It appears that this 
higher charge-to-mass ratio may not be due to the specific charges of the negative SX particles but may 
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relate to the additional contribution of the propellant and the precipitation of impurities such as water 
upon propellant vaporisation. Whilst there has been no published ELPI studies with a Serevent product, 
a highly electronegative charge signal in the lower stages (<0.6µm) of an ELPI for a predominately net 
positively charged salbutamol sulphate aerosol was found by Kwok et al. for the excipient-free Ventolin 
pMDI product (10). 
Bipolar charge-to-mass ratio determination of Seretide™ 250 
The mass deposition profile of FP and SX from a commercial Seretide™ 250 pMDI in the bp-NGI at 0 
V and ±3 kV are shown in Figures 9 A-D respectively, and summarised in Tables iv a for FP and iv b for 
SX. At 0 V, the majority (> 85%) of the FP and SX particles are collected on the glass filters at the base 
of the precipitators. Upon applying high voltage (±3 kV), similar quantities of FP and SX were recovered 
from each precipitation section of the bp-NGI, indicating efficient bifurcation of the fine particle cloud 
within the system. The mass ratio of negatively to positively charged particles of precipitated FP was 
2.6:1, which is similar to that obtained for the Flixotide™ product.  
The ratio of negatively to positively charged SX particles by mass was 1.7:1. This was not in good 
agreement with the Serevent pMDI, which indicated a mass ratio of negatively to positively charged SX 
particles of 0.6:1. These data suggest that the presence of a relatively high dose of FP (10:1 dose ratio 
of FP:SX) may have a significant impact on the mass deposition profile of SX within the electrostatic 
precipitator. The different deposition profile of SX particles may suggest that SX, which is predominately 
positively charged, has an attractive tendency to the negatively charged FP particles which could alter 
its deposition profiles and its response to an electric field. Agglomerate formation of FP with SX has 
previously been reported on individual impactor stages for Seretide™ pMDI formulation by Raman 
spectroscopy (27). 
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The charge measurements of FP and SX collected per shot recorded at 0V and ±3 kV are shown in 
Figure 10 A and B, respectively. At 0V, the net charge measurement in each precipitation was low and 
positive. At ±3 kV, the average charge measured per shot for the negative and positive precipitators 
were -0.37 ± 0.01nC and +0.47 ± 0.01nC, respectively, with an average net charge per shot of +0.10 ± 
0.01nC. These results are similar to the behaviour of Flixotide, with the fine particle dose being 
electropositive. 
The bipolar charge-to-mass ratios of the precipitated FP and SX from a Seretide™ 250 pMDI are shown 
in Figure 11. The charge-to-mass ratios of the negatively and positively charged particles were -11.5 ± 
0.5 pC/μg and +42.8 ± 4.6 pC/μg, respectively, with a net charge-to-mass ratio of +2.6 ± 0.4 pC/μg. 
These findings suggest that presence of salmeterol has little effect on the electrostatic precipitation 
properties, which was dominated by the charging behaviour of FP and the influence of excipients leading 
to the higher than expected positive charge-to-mass ratio values. 
A summary of the percentage mass distributions recorded by the precipitation sections of the bp-NGI of 
the three drug products are summarised in Table v. For both Flixotide™ and Seretide™ products, the 
FP exhibited similar profiles with 62.0 ± 2.3% and 61.2 ± 4.5% negatively charged particles, 25.0 ± 3.2% 
and 24.8 ± 2.7% of positively charged particles and 13.0 ± 1.2% and 14.1 ± 2.0% non-precipitated dose, 
respectively. These data indicated the presence of SX in combination with FP had little effect on the 
electrostatic properties of FP. For SX, the precipitation profiles of SX from Seretide™ and Serevent™ 
were directly affected by the presence of FP. The percentage of negatively charged particles of SX 
increased over 2.5-fold within the combination Seretide™ drug product. This concomitantly led to a 
similar decrease in the amount of positively charged particles in the combination drug product.  
 
CONCLUSIONS 
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The present study demonstrates that the bipolar Next Generation Impactor may be successfully used 
to quantify the bipolar charge-to-mass ratios of the ISM from commercial pMDI formulations whilst at 
the same time allowing for complete recovery of the emitted dose from the inhaler. More negatively 
charged particles were produced than positively charged from both Flixotide™ and Seretide™ although 
the charge-to-mass ratios of the positively charged particles were larger in magnitude than the 
negatively charged indicating the possibility of competing triboelectric charging mechanisms. In the case 
of Serevent™, the SX particles showed a propensity to become more positively charged than negatively 
charged, however, the charge-to-mass ratios of the negatively charged particles were significantly larger 
in magnitude. The difference in behaviour between the SX particles in Serevent™ and Seretide™ may 
be attributed to the presence of FP-SX aggregates in Seretide™ which are not present in Serevent™. 
The results of the study illustrate that the bp-NGI is an effective tool to quantify the bipolar charge-to-
mass ratios of respirable aerosol particles produced by the three commercially available pMDIs. 
Comparisons with data generated by Kwok et al. with the ELPI indicated that the positive charge values 
recorded may have been contributed to by the presence of ice crystals exiting the inhaler as the pMDI 
propellant evaporated (10). A control experiment is suggested to characterise a propellant only pMDI 
formulation; values for the propellant bipolar charge could be subtracted from the overall bipolar charge 
in order to determine the contribution of the API to the charge values. Unfortunately placebo pMDI 
canisters of Flixotide™, Serevent™ and Seretide™ are not commercially available and could not be 
analysed for this study.  
Further studies suggested include measuring the bipolar charge distributions of other pMDI formulations 
such as QVAR® and Ventolin® with the bp-NGI and comparing the bipolar charge-to-mass ratio values 
recorded with net charge-to-mass ratio values published in the literature. Other variables such as flow 
rate, dosage strength, humidity and the type and colour of the polymer used to disperse a pMDI could 
also be investigated as well as the addition of a spacer device. The bipolar charge of only the combined 
fine particle fraction from the bp-NGI from stages 2 and below of the NGI were collected, additional 
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experiments could also be performed to connect the electrostatic precipitation system to the other 
stages in order to build up a more accurate picture of the relationship between aerosol particle charge 
and aerodynamic diameter cut off. 
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Table and Figure Legends 
Table i: Comparison of Flixotide™ 250 and Serevent™ 25 pMDI performance as determined with a 
conventional NGI and the bp-NGI. 
Table ii:  Mass and percentage mass of FP particles collected from each section of the bp-NGI 
precipitation system from 5 shots Flixotide™ 250 (n=3, mean ± SD) at A, 0 V and B ±3 kV. 
Table iii:  Mass and percentage mass SX particles collected from each section of the bp-NGI 
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precipitation system from 5 shots of Serevent™ 25 (n=3, mean ± SD) at A, 0 V and B ±3 kV. 
Table iv: Mass and percentage mass of a, FP and b, SX particles collected from each section of bp-
NGI precipitation system from 5 shots of a combination Seretide™ formulation (n=3, mean ± SD) at A, 
0 V and B ±3 kV. 
Table v: Percentages of negatively charged, positively charged and uncharged Particles of FP and SX 
in Flixotide™, Seretide™ and Serevent™ pMDIs ± SD, n=3. 
Figure 1: Design of the BP-NGI 
Figure 2: Theoretical collection efficiency of bp-NGI plotted against particle diameter cut off diameter 
of NGI stages 1-8 for 100, 200 and 300 electrons per particle. 
Figure 3: Percentage mass of FP particles collected from each section of bp-NGI precipitation system 
from 5 shots of Flixotide™ 250 (n=3, mean ± SD) at A, 0 Volts and B ±3000 Volts. 
Figure 4: Charge measurements of FP particles collected from each section of the bp-NGI 
precipitation system from 5 shots of Flixotide™ 250 (n=3, mean ± SD) at A, 0 Volts and B ±3000 Volts. 
Figure 5: Bipolar charge-to-mass ratios of FP particles from 5 shots of Flixotide™ 250 (n=3, mean ± 
SD). 
Figure 6: Percentage mass of salmeterol particles collected from each section of bp-NGI precipitation 
system from 5 shots of Serevent™ 25 (n=3, mean ± SD) at A, 0 Volts and B ±3000 Volts. 
Figure 7: Charge measurements of SX particles collected from each section of the bp-NGI 
precipitation system from 5 shots of Serevent™ 25 (n=3, mean ± SD) at A, 0 Volts and B ±3000 Volts. 
Figure 8: Bipolar charge-to-mass ratios of SX particles from 5 shots of Serevent™ 25 (n=3, mean ± 
SD). 
Figure 9: Percentage mass of FP particles collected at A, 0 Volts and B ±3000 Volts and percentage 
mass of salmeterol particles at C, 0 Volts and D ±3000 Volts collected from each section of bp-NGI 
precipitation system from 5 shots of Seretide™ 250 (n=3, mean ± SD). 
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Figure 10: Charge measurements of SX and FP particles collected from each section of the bp-NGI 
precipitation system from 5 shots of Seretide™ 250 (n=3, mean ± SD) at A, 0 Volts and B ±3000 Volts. 
Figure 11: Bipolar charge-to-mass ratios of SX and FP particles from 5 shots of Seretide™ 250 (n=3, 
mean ± SD). 
 
Tables 
Table i. 
 
pMDI 
Conventional NGI bp-NGI 
ED (% of RD) ISM (% of RD) ED (% of RD) ISM (% of RD) 
Flixotide™ 250 89.8 ± 4.0 50.2 ± 2.6 91.0 ± 6.0 49.8 ± 5.7 
Serevent™ 25 88.5 ± 4.8 58.3 ± 3.6 91.5 ± 11.6 64.1 ± 9.0 
 
Table ii.  
 
FP 
 
0 V 
 
±3 kV 
 
  
Negative 
Precipitator 
(μg ± SD) 
 
 
Positive 
Precipitator 
(μg ± SD) 
 
 
Negative 
Precipitator 
(% ± SD) 
 
 
Positive 
Precipitator 
(% ± SD) 
 
 
Negative 
Precipitator 
(μg ± SD) 
 
 
Positive 
Precipitator 
(μg ± SD) 
 
 
Negative 
Precipitator 
(% ± SD) 
 
 
Positive 
Precipitator 
(% ± SD) 
 
 
Tube 
 
 
2.8 ± 0.3 
 
0.6 ± 0.3 
 
1.9 ± 0.2 
 
0.4 ± 0.2 
 
95.2 ± 3.6 
 
35.0 ± 2.5 
 
62.0 ± 2.3 
 
23.8 ± 1.7 
 
Electrode 
 
 
8.3 ± 1.1 
 
3.7 ± 1.1 
 
5.5 ± 0.8 
 
2.4 ± 0.7 
 
38.4 ± 4.9 
 
95.1 ± 2.0 
 
25.0 ± 3.2 
 
64.7 ± 1.4 
 
Filter 
 
 
139.0 ± 9.3 
 
145.2 ± 2.3 
 
92.7 ± 6.2 
 
97.2 ± 5.2 
 
19.9 ± 1.6 
 
17.0 ± 2.3 
 
13.0 ± 1.2 
 
11.6 ± 1.6 
 
Total 
 
 
150.0 ± 10.7 
 
 
149.4 ± 6.8 
 
100.0 ± 7.1 
 
100.0 ± 6.1 
 
153.5 ± 10.0 
 
147.0 ± 6.8 
 
100.0 ± 6.6 
 
100.00 ± 4.6 
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Table iii.  
 
 
SX 
 
0 V 
 
±3 kV 
 
  
Negative 
Precipitator 
(μg ± SD) 
 
 
Positive 
Precipitator 
(μg ± SD) 
 
 
Negative 
Precipitator 
(% ± SD) 
 
 
Positive 
Precipitator 
(% ± SD) 
 
 
Negative 
Precipitator 
(μg ± SD) 
 
 
Positive 
Precipitator 
(μg ± SD) 
 
 
Negative 
Precipitator 
(% ± SD) 
 
 
Positive 
Precipitator 
(% ± SD) 
 
 
Tube 
 
 
1.0 ± 0.5 
 
0.6 ± 0.1 
 
8.2 ± 3.8 
 
5.1 ± 1.4 
 
3.9 ± 0.4 
 
10.8 ± 0.9 
 
20.1 ± 2.29 
 
58.9 ± 5.7 
 
Electrode 
 
 
0.5 ± 0.1 
 
0.8 ± 0.2 
 
4.2 ± 0.8 
 
6.4 ± 1.8 
 
10.1 ± 1.2 
 
3.6 ± 0.9 
 
65.7 ± 6.9 
 
27.9 ± 5.5 
 
Filter 
 
 
10.3 ± 0.7 
 
10.8 ± 0.5 
 
87.6 ± 6.0 
 
88.5 ± 3.8 
 
2.4 ± 0.2 
 
2.2 ± 0.1 
 
14.2 ± 1.0 
 
13.6 ± 0.7 
 
Total 
 
 
11.9 ± 1.3 
 
12.2 ± 0.8 
 
100.0 ± 10.6 
 
100.0 ± 6.1 
 
16.3 ± 1.8 
 
16.5 ± 1.9 
 
100.0 ± 10.2 
 
100.0 ± 11.9 
 
 
 
 
Table iva. 
 
FP 
 
 
0 V 
 
±3 kV 
 
  
Negative 
Precipitator 
(μg ± SD) 
 
 
Positive 
Precipitator 
(μg ± SD) 
 
 
Negative 
Precipitator 
(% ± SD) 
 
 
Positive 
Precipitator 
(% ± SD) 
 
 
Negative 
Precipitator 
(μg ± SD) 
 
 
Positive 
Precipitator 
(μg ± SD) 
 
 
Negative 
Precipitator 
(% ± SD) 
 
 
Positive 
Precipitator 
(% ± SD) 
 
 
Tube 
 
 
2.3 ± 0.7 
 
6.9 ± 1.6 
 
1.6 ± 0.5 
 
4.4 ± 1.0 
 
105.6 ± 7.8 
 
40.7 ± 2.2 
 
61.2 ± 4.5 
 
23.5 ± 1.3 
 
Electrode 
 
 
6.1 ± 1.3 
 
8.7 ± 2.9 
 
4.3 ± 0.9 
 
5.5 ± 1.9 
 
42.8 ± 4.7 
 
108.4 ± 7.8 
 
24.7 ± 2.7 
 
62.7 ± 4.5 
 
Filter 
 
 
133.8 ± 6.1 
 
141.8 ± 7.7 
 
94.1 ± 4.3 
 
90.1 ± 4.9 
 
24.4 ± 3.4 
 
23.8 ± 3.1 
 
14.1 ± 2.0 
 
13.8 ± 1.8 
 
Total 
 
 
142.2 ± 8.0 
 
 
157.4 ± 12.2 
 
100.0 ± 5.6 
 
100.0 ± 7.7 
 
172.8 ± 15.8 
 
 
172.9 ± 13.0 
 
100.0 ± 9.2 
 
100.0 ± 7.5 
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Table ivb. 
 
 
 
SX 
 
 
0 V 
 
±3 kV 
 
  
Negative 
Precipitator 
(μg ± SD) 
 
 
Positive 
Precipitator 
(μg ± SD) 
 
 
Negative 
Precipitator 
(% ± SD) 
 
 
Positive 
Precipitator 
(% ± SD) 
 
 
Negative 
Precipitator 
(μg ± SD) 
 
 
Positive 
Precipitator 
(μg ± SD) 
 
 
Negative 
Precipitator 
(% ± SD) 
 
 
Positive 
Precipitator 
(% ± SD) 
 
Tube 
Tube 
 
 
0.7 ± 0.1 
 
0.8 ± 0.2 
 
5.4 ± 1.0 
 
6.1 ± 1.4 
 
6.7 ± 0.3 
 
4.6 ± 0.4 
 
52.8 ± 2.7 
 
31.6 ± 2.7 
 
Electrode 
 
 
0.5 ± 0.1 
 
1.1 ± 0.3 
 
4.2 ± 1.0 
 
8.2 ± 1.8 
 
3.8 ± 0.3 
 
7.4 ± 0.4 
 
30.1 ± 2.2 
 
51.2 ± 2.4 
 
Filter 
 
 
10.6 ± 0.7 
 
11.0 ± 0.7 
 
90.4 ± 5.4 
 
85.7 ± 5.4 
 
2.2 ± 0.4 
 
2.5 ± 0.7 
 
17.2 ± 2.9 
 
17.2 ± 4.9 
 
Total 
 
 
11.8 ± 0.9 
 
 
12.9 ± 1.1 
 
100.0 ± 7.5 
 
100.0 ± 8.6 
 
12.6 ± 1.0 
 
 
14.5 ± 1.5 
 
100.0 ± 7.8 
 
100.0 ± 10.0 
 
 
 
 
Table v.  
 
 FP SX 
 
 
   Flixotide™  
 
Seretide™ Seretide™ Serevent™ 
 
Negatively charged 
particles 
(% ± SD) 
 
62.0 ± 2.3 
 
61.2 ± 4.5 
 
52.8 ± 2.7 
 
20.1 ± 2.3 
 
Positively charged 
particles 
(% ± SD) 
 
25.0 ± 3.2 
 
24.8 ± 2.7 
 
30.1 ± 2.2 
 
65.7 ± 6.9 
 
Uncharged particles 
(% ± SD) 
 
 
13.0 ± 1.2 
 
14.1 ± 2.0 
 
17.2 ± 2.9 
 
14.2 ± 1.0 
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Figures 
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Figure 11 
 
 
 
